suberoylanilide hydroxamic acid
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent histone deacetylase inhibitor |
| gptkbp:alsoKnownAs |
gptkb:SAHA
gptkb:vorinostat |
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX50
|
| gptkbp:CASNumber |
149647-78-9
|
| gptkbp:category |
orphan drugs
anilides hydroxamic acids |
| gptkbp:chemicalFormula |
C14H20N2O3
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:discoveredBy |
gptkb:Paul_Marks
|
| https://www.w3.org/2000/01/rdf-schema#label |
suberoylanilide hydroxamic acid
|
| gptkbp:mechanismOfAction |
inhibits histone deacetylases
|
| gptkbp:molecularWeight |
264.32 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea anorexia fatigue thrombocytopenia |
| gptkbp:usedFor |
treatment of cutaneous T-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:vorinostat
|
| gptkbp:bfsLayer |
6
|